Sinaptica Therapeutics Selected for StartUp Health’s Alzheimer’s Moonshot
2024年5月22日 - 11:00PM
ビジネスワイヤ(英語)
Moonshot supported by Gates Ventures and
Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate
innovation around Alzheimer’s
Sinaptica is one of 14 companies initially
selected that are advancing innovative solutions for Alzheimer’s to
commercialization and scalability
Collaboration will support the company’s Phase
3 clinical development plans based on unprecedented Phase 2 data in
Alzheimer’s showing >80% disease slowing on cognitive &
functional endpoints
Sinaptica Therapeutics, Inc., a clinical-stage company leading
the development of a new class of personalized neuromodulation
therapeutics to treat Alzheimer’s (AD) and other neurodegenerative
diseases, today announced that it has been selected to join StartUp
Health’s Alzheimer’s Moonshot. This bold new initiative and global
community of founders and funders collaborating to prevent,
diagnose, manage, and ultimately cure Alzheimer's disease is
supported by the Alzheimer’s Drug Discovery Foundation (ADDF) and
Gates Ventures.
The collaboration will help support the global development of
Sinaptica’s patented neuromodulation therapy, which takes a
precision medicine approach targeting the Default Mode Network in
the brain. The company has prioritized mild/moderate Alzheimer’s
Disease as its first indication and is preparing for a pivotal
Phase 3 trial in 2025.
“Sinaptica is honored to be included in this hand-selected group
of innovators working to end Alzheimer’s – a goal which we believe
will require combinatorial approaches,” said Sinaptica CEO Ken
Mariash. “Sinaptica brings a bold new personalized neuromodulation
approach that can be combined with virtually any drug, given its
near-total lack of side effects. Also, we know diagnostics are a
key piece of the puzzle and will look to combine our novel
electrophysiological biomarker with those of others in the
Moonshot, to better characterize the disease and bring a more
personalized, precision medicine approach to Alzheimer’s
treatments.”
“We’re excited to welcome Sinaptica Therapeutics to the
Alzheimer’s Moonshot and the StartUp Health family,” said Steven
Krein, CEO and co-founder of StartUp Health. “We created the
Alzheimer’s Moonshot to bring together trailblazers, support new
approaches and rapidly accelerate progress in this challenging
disease. Sinaptica is a perfect fit and we look forward to
partnering with them.”
Sinaptica is building on unprecedented positive Phase 2 data in
Alzheimer’s published by the company’s scientific co-founders,
showing greater than 80% disease slowing on all four gold-standard
AD cognitive and functional clinical endpoints, in the
peer-reviewed Oxford University Press journal, Brain. Additional
exciting 52-week data from the Phase 2 study will also be published
in an upcoming issue of a peer-reviewed journal. Sinaptica’s
technology has been granted FDA Breakthrough Device Designation,
and the company is preparing for a larger Phase 3 clinical trial in
Alzheimer s patients at multiple sites.
About StartUp Health
Since 2011, StartUp Health has been on a mission to solve the
biggest health challenges of our time by creating and sustaining a
global ecosystem of health moonshot communities. StartUp Health has
provided support to more than 1,000 founders and contributed to the
development of more than 500 health innovation companies. Our
valued partners include The Helmsley Charitable Trust, Alzheimer’s
Drug Discovery Foundation (ADDF) and Gates Ventures in addition to
nearly 100 families and mission-aligned organizations. Visit
startuphealth.com.
About Sinaptica Therapeutics
Sinaptica Therapeutics is a clinical-stage neuromodulation
therapeutics company leading the development of a new class of
personalized therapeutics to revolutionize the treatment of
Alzheimer’s and neurodegenerative diseases. The company utilizes a
patented novel, non-invasive approach to treating Alzheimer’s via
precision neurostimulation of a key brain network involved in
memory, the Default Mode Network. This novel approach slowed
disease progression by >80% on all four gold-standard cognitive
and functional clinical endpoints in a placebo-controlled Phase 2
clinical study, with results published in the peer-reviewed Oxford
University Press journal, Brain. The technology was granted
Breakthrough Device Designation by the FDA in 2022 and the company
is preparing for a pivotal randomized controlled clinical trial in
2025. Sinaptica’s mission is to bring a safe, effective, and
non-invasive neuromodulation therapy to Alzheimer’s patients that
can help to significantly slow the progression of both cognitive
and functional decline. Learn more at sinapticatx.com and follow us
on LinkedIn and X @SinapticaTX.
The SinaptiStim™ System is for investigational use only. It has
not been approved by the U.S. Food and Drug Administration and is
not available for commercial sale in any geography.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522488674/en/
Kira Gordon, BrightPoint kira@brightpointny.com 646-243-4920